Hemangioma medical therapy: Difference between revisions
Jump to navigation
Jump to search
Nawal Muazam (talk | contribs) No edit summary |
Sergekorjian (talk | contribs) |
||
| Line 11: | Line 11: | ||
:*[[Interferon]] | :*[[Interferon]] | ||
:*[[Vincristine]] | :*[[Vincristine]] | ||
*These agents have also been used for:<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | |||
:*Multifocal disease | |||
:*Visceral involvement | |||
:*Segmental distribution | |||
:*Airway obstruction | |||
:*Periorbital lesions | |||
===Intense pulsed light=== | ===Intense pulsed light=== | ||
*IPL flash lamps emit broadband polychromatic high-intensity light in the wavelength spectrum ranging 515-1200nm.<ref name="CaucanasPaquet2011">{{cite journal|last1=Caucanas|first1=Marie|last2=Paquet|first2=Philippe|last3=Henry|first3=Frédérique|last4=Piérard-Franchimont|first4=Claudine|last5=Reginster|first5=Marie-Annick|last6=Piérard|first6=Gérald E.|title=Intense Pulsed-Light Therapy for Proliferative Haemangiomas of Infancy|journal=Case Reports in Dermatological Medicine|volume=2011|year=2011|pages=1–5|issn=2090-6463|doi=10.1155/2011/253607}}</ref> | *IPL flash lamps emit broadband polychromatic high-intensity light in the wavelength spectrum ranging 515-1200nm.<ref name="CaucanasPaquet2011">{{cite journal|last1=Caucanas|first1=Marie|last2=Paquet|first2=Philippe|last3=Henry|first3=Frédérique|last4=Piérard-Franchimont|first4=Claudine|last5=Reginster|first5=Marie-Annick|last6=Piérard|first6=Gérald E.|title=Intense Pulsed-Light Therapy for Proliferative Haemangiomas of Infancy|journal=Case Reports in Dermatological Medicine|volume=2011|year=2011|pages=1–5|issn=2090-6463|doi=10.1155/2011/253607}}</ref> | ||
Revision as of 19:05, 20 November 2015
|
Hemangioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hemangioma medical therapy On the Web |
|
American Roentgen Ray Society Images of Hemangioma medical therapy |
|
Risk calculators and risk factors for Hemangioma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]
Overview
The majority of cases of hemangioma are self-limited. Patients with small, stable hemangiomas in non-vital sites are treated with "wait and see" approach, whereas patients with fast growth of hemangioma are treated medically.[1]
Medical Therapy
- Medical and surgical options are available for the treatment of “problematic” hemangiomas.[2]
- Medical management includes one or more systemic therapies.
- For massive and life-threatening disease:[2]
- These agents have also been used for:[2]
- Multifocal disease
- Visceral involvement
- Segmental distribution
- Airway obstruction
- Periorbital lesions
Intense pulsed light
- IPL flash lamps emit broadband polychromatic high-intensity light in the wavelength spectrum ranging 515-1200nm.[3]
- They target vessels at various depths inside the skin.
- The effect relies on selective photothermolysis.
- The indication spectrum includes vascular tumors including hemangiomas.
Propranolol
- A paradigm shift has occurred regarding the treatment of hemangiomas over the past few years.[2]
- Propranolol, a nonselective β-adrenergic antagonist, was serendipitously discovered to cause regression of proliferating hemangiomas in newborns receiving treatment for cardiovascular disease.
- Numerous studies demonstrating the success of propranolol for shrinking hemangiomas
- Over ninety percent of patients have dramatic reduction in the size of their hemangiomas as early as 1-2 weeks following the first dose of propranolol.
- Dosing for propranolol in treating hemangiomas is recommended to be 2-3 mg/kg separated into two or three-times-a-day regimens.
- These doses are dramatically below the concentration employed for cardiovascular conditions in children.[2]
References
- ↑ Zheng JW, Zhang L, Zhou Q, et al. A practical guide to treatment of infantile hemangiomas of the head and neck. Int J Clin Exp Med. 2013;6(10):851-60.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832322/?report=classic#
- ↑ 2.0 2.1 2.2 2.3 2.4 Richter, Gresham T.; Friedman, Adva B. (2012). "Hemangiomas and Vascular Malformations: Current Theory and Management". International Journal of Pediatrics. 2012: 1–10. doi:10.1155/2012/645678. ISSN 1687-9740.
- ↑ Caucanas, Marie; Paquet, Philippe; Henry, Frédérique; Piérard-Franchimont, Claudine; Reginster, Marie-Annick; Piérard, Gérald E. (2011). "Intense Pulsed-Light Therapy for Proliferative Haemangiomas of Infancy". Case Reports in Dermatological Medicine. 2011: 1–5. doi:10.1155/2011/253607. ISSN 2090-6463.